Alnylam taps RNAi candidate for hemophilia; California Biocom CEO has China on his mind;

@FierceBiotech: Aura BioSciences banks $4.5M from private backers. Report | Follow @FierceBiotech

@JohnCFierce: In matchup with Humira, tofacitinib pill lines up on efficacy, nothing new on safety Bloomberg. News | Follow @JohnCFierce

@RyanMFierce: Sounds like bad news for Seattle-area biotech. Dendreon $DNDN has a conf. call this afternoon to discuss restructuring. Report | Follow @RyanMFierce

> Alnylam Pharmaceuticals ($ALNY) said it has tapped ALN-APC, an RNAi drug for hemophilia, for its program to move its gene-silencing drugs in the clinical development. Release

> Massachusetts has pulled a $750,000 loan--part of its $1 billion life sciences R&D fund--from ECI Biotech because of differences over how the money could be used and changes in the infection-detection company's financial condition. Report

> Given the scant financials of biotech startups makes quantitative analysis difficult for investors; look at qualitative drivers of biotech value--product pipeline, patents, talented management, durable partnerships and access to funds. Item

> "China is big on my mind these days," says Joe Panetta CEO of the southern California Biocom life sciences industry association. "My goal is to build a working relationship between Southern California and China's pharma and device companies." Interview

Pharma News

@FiercePharma: Once again... RT @Loftus: Drugs Beat Stents Against Stroke Recurrence in Study, via @WSJ. Item | Follow @FiercePharma

> Deal-minded analysts eye Bayer, AZ for M&A. Article

> Genzyme apologizes for latest Fabrazyme delay. News 

> Chairman: Ranbaxy set to launch Lipitor as planned. Story  

Vaccines News

> Cuba announces launch of world's first lung cancer vax. News 

> Dendreon cancels GSK Provenge contract. Article

> Related bacterium could create viable TB vax. Story

> Merck finishes animal vaccine plant overhaul. News

> HIV envelope protein approach elicits vaccine immune response. Item

Manufacturing News

> Price overlap blurs quality between generic, substandard drugs. Story

> Pfizer pushes iPads toward factory floor. News

> Brioschi antacid on a comeback, bringing manufacturing jobs to NY. Article

> Labor follows lead of Genzyme, others in green tie-up. Report

> Pharma's cold need is opportunity in all parts of supply chain. Story 

> Study finds quality risk gap between U.S., Puerto Rico plants. News

Suggested Articles

Paragon Biosciences has hired Kerensa Jimenez as the new CEO of its capital markets group Paragon Health Capital.

Regeneron has taken a step closer to getting a green light for its experimental high cholesterol drug as the FDA allows a swift review of evicanumab.

An analysis of Gilead’s remdesivir clinical trials found the studies “failed to provide equal representation of Black, Latinx and Native Americas."